BioWorld

Aug. 29, 2005

DOV Halts Ocinaplon Phase III To Check Liver Enzyme Status

Because of potential liver toxicity risks, DOV Pharmaceutical Inc. shut down a Phase III trial of its investigational anti-anxiety agent ocinaplon, a setback that could cause the company to drop the drug altogether. (BioWorld Today) Read More

Inyx Paying UCB $37.5M To Acquire UK Subsidiary

Able Laboratories: The Rise And Fall Of A Generic Firm

Renovis' Sciatica Therapy Fizzles In Phase II Studies

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026

SERCA inhibitor shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers...